rs763706988
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_080916.3(DGUOK):c.763_766dup(p.Phe256Ter) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000682 in 1,613,790 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000055 ( 0 hom. )
Consequence
DGUOK
NM_080916.3 frameshift
NM_080916.3 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -1.01
Genes affected
DGUOK (HGNC:2858): (deoxyguanosine kinase) In mammalian cells, the phosphorylation of purine deoxyribonucleosides is mediated predominantly by two deoxyribonucleoside kinases, cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. The protein encoded by this gene is responsible for phosphorylation of purine deoxyribonucleosides in the mitochondrial matrix. In addition, this protein phosphorylates several purine deoxyribonucleoside analogs used in the treatment of lymphoproliferative disorders, and this phosphorylation is critical for the effectiveness of the analogs. Alternative splice variants encoding different protein isoforms have been described for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.0875 CDS is truncated, and there are 1 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-73958199-A-ATGAT is Pathogenic according to our data. Variant chr2-73958199-A-ATGAT is described in ClinVar as [Likely_pathogenic]. Clinvar id is 8155.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DGUOK | NM_080916.3 | c.763_766dup | p.Phe256Ter | frameshift_variant | 6/7 | ENST00000264093.9 | NP_550438.1 | |
DGUOK-AS1 | NR_104030.1 | n.313_314insATCA | non_coding_transcript_exon_variant | 2/2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DGUOK | ENST00000264093.9 | c.763_766dup | p.Phe256Ter | frameshift_variant | 6/7 | 1 | NM_080916.3 | ENSP00000264093 | P1 | |
DGUOK-AS1 | ENST00000667561.3 | n.308-10265_308-10264insATCA | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152178Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152178
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251464Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135906
GnomAD3 exomes
AF:
AC:
5
AN:
251464
Hom.:
AF XY:
AC XY:
3
AN XY:
135906
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000547 AC: 8AN: 1461612Hom.: 0 Cov.: 30 AF XY: 0.00000688 AC XY: 5AN XY: 727136
GnomAD4 exome
AF:
AC:
8
AN:
1461612
Hom.:
Cov.:
30
AF XY:
AC XY:
5
AN XY:
727136
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152178Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74334
GnomAD4 genome
AF:
AC:
3
AN:
152178
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74334
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Mitochondrial DNA depletion syndrome 3 (hepatocerebral type) Pathogenic:4
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Jul 25, 2022 | ACMG classification criteria: PVS1 strong, PS4 moderated, PM2 moderated, PM3 moderated - |
Pathogenic, no assertion criteria provided | clinical testing | Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City | Sep 26, 2019 | - - |
Likely pathogenic, criteria provided, single submitter | research | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 25, 2024 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 09, 2017 | The c.763_766dupGATT pathogenic variant in the DGUOK gene has been reported previously in association with mitochondrial depletion syndrome in several unrelated individuals who were homozygous for c.763_766dupGATT or heterozygous for c.763_766dupGATT and another variant in the DGUOK gene (Mancuso et al., 2003; Dimmock et al., 2008; Villarroya et al., 2009Al-Hussaini et al., 2014). Fibroblasts from an individual homozygous for this variant showed 1-2.6% enzyme activity compared to controls (Mousson et al., 2007). The c.763_766dupGATT variant results in the normal codon, Phenylalanine 256, being replaced by a Stop codon, denoted p.F256X. This pathogenic variant is predicted to cause loss of normal protein function through protein truncation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 30, 2023 | This sequence change creates a premature translational stop signal (p.Phe256*) in the DGUOK gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 22 amino acid(s) of the DGUOK protein. This variant is present in population databases (rs763706988, gnomAD 0.009%). This premature translational stop signal has been observed in individuals with mitochondrial DNA depletion syndrome (PMID: 14568816, 16263314, 17073823, 18205204, 19265691, 24321534). This variant is also known as c.796insTGAT. ClinVar contains an entry for this variant (Variation ID: 8155). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 02, 2021 | - - |
DGUOK-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 25, 2023 | Variant summary: DGUOK c.763_766dupGATT (p.Phe256X), also referred to as c.796insTGAT in the literature, results in a premature termination codon and although nonsense mediated decay is not expected, it is predicted to cause a truncation of the encoded protein, a commonly known mechanism for disease. The variant allele was found at a frequency of 2e-05 in 251464 control chromosomes (gnomAD). c.763_766dupGATT has been reported in the literature as a biallelic genotype in individuals affected with DGUOK-Related Disorders including mitochondrial DNA depletion syndrome (e.g. Slama_2005, Mousson de Camaret_2007, Dimmock_2008). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function and found the variant results in <5% of normal activity (e.g. Mousson de Camaret_2007). The following publications have been ascertained in the context of this evaluation (PMID: 18205204, 17073823, 16263314). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at